Current breast cancer clinical trials

Home: Educational Supplement: Appendix

Planning Committee

Planning Committee Chair:
Jeffrey Abrams, M.D.
Senior Investigator
Clinical Investigation Branch
Cancer Therapy Evaluation Program
National Cancer Institute
Bethesda, Maryland
Marietta Anthony, Ph.D.
Director, Women’s Health Research
Department of Pharmacology
Georgetown University Medical Center
Washington, DC
Alan Coates, M.D., FRACP
International Breast Cancer Study Group
Chief Executive Officer
Australian Cancer Society
Sydney, Australia
Karen H. Antman, M.D.
Professor of Medicine
College of Physicians and Surgeons of Columbia University
Chief, Division of Medical Oncology
Director, Herbert Irving Comprehensive
Cancer Center
New York, New York
Nancy E. Davidson, M.D.
Professor
Johns Hopkins Oncology Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Christine D. Berg, M.D.
Director, Suburban Hospital Cancer Center
Affiliated with Johns Hopkins Oncology
Center
Bethesda, Maryland
Patricia Eifel, M.D.
Professor of Radiation Oncology
M.D. Anderson Cancer Center
University of Texas
Houston, Texas
John A. Bowersox
Communications Specialist
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland
Jerry M. Elliott
Program Analysis and Management Officer
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland
John H. Ferguson, M.D.
Potomac, Maryland
John L. Bryant, Ph.D.
Associate Professor of Biostatistics
University of Pittsburgh
Director, Biostatistical Center
National Surgical Adjuvant Breast and Bowel Project
Pittsburgh, Pennsylvania
Patricia A. Ganz, M.D.
Professor, UCLA Schools of Medicine and Public Health
Director, Division of Cancer Prevention and Control Research
Jonsson Comprehensive Cancer Center
Los Angeles, California
Gabriel N. Hortobagyi, M.D., FACP
Professor and Chairman
Department of Breast Medical Oncology
M.D. Anderson Cancer Center
University of Texas
Houston, Texas
Charles R. Sherman, Ph.D.
Deputy Director
Office of Medical Applications of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland
Karen Eubanks Jackson
National President and Founder
Sisters Network, Inc.
Houston, Texas
Sheila E. Taube, Ph.D.
Associate Director of Cancer Diagnosis Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
Amy S. Langer, M.B.A.
Executive Director
National Alliance of Breast Cancer
Organizations (NABCO)
New York, New York
Ann Thor, M.D.
Professor
Departments of Pathology and Surgery
Northwestern University Medical School
Evanston Northwestern Healthcare
Evanston, Illinois
Daniel J. O’Neal III, R.N., M.A.
Chief
Office of Science Policy and Public Liaison
National Institute of Nursing Research
National Institutes of Health
Bethesda, Maryland
William C. Wood, M.D., FACS
Joseph Brown Whitehead Professor and Chairman
Department of Surgery
Emory University School of Medicine
Atlanta, Georgia
Lori Pierce, M.D.
Associate Professor
Department of Radiation Oncology
University of Michigan Medical Center
Ann Arbor, Michigan
JoAnne Zujewski, M.D.
Senior Medical Oncologist
Division of Clinical Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
 

 

Top | Main Menu

 

Main Menu
Contents
I.
Overview
II.
Factors Used To Select Adjuvant Therapy
III.
Adjuvant Hormone Therapy
IV.
Adjuvant Chemotherapy
V.
Adjuvant Postmastectomy Radiotherapy
VI.
Influences of Treatment-Related Side Effects and Quality-of-Life Issues on Individual Decision-Making About Adjuvant Therapy
Breast Cancer Update's web site
Search our site
Home · Contact us
Terms of use and general disclaimer